The B4GALT1 Knockout SK-HEP-1 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population derived from the human SK-HEP-1 cell line, featuring targeted disruption of the B4GALT1 gene. This knockout model is supplied as a ready-to-use heterogeneous mixture of cells carrying diverse loss-of-function mutations at the B4GALT1 locus, providing a valuable tool for studying glycosylation-dependent processes without the limitations of a single clonal isolate. The use of polyclonal knockout cells helps mitigate clonal variation and ensures a broader representation of genetic edits, making this product suitable for high-content screening, functional genomics, and biomarker discovery in liver cancer research.
The host SK-HEP-1 cell line originates from the ascitic fluid of a patient with hepatic adenocarcinoma and is characterized by a unique hybrid phenotype that co-expresses both epithelial and endothelial markers. This unusual plasticity makes SK-HEP-1 an established in vitro model for investigating liver cancer biology, endothelial transdifferentiation, and tumor-host microenvironment interactions. Its dual nature allows researchers to probe molecular mechanisms underlying the epithelial-to-endothelial transition, a process increasingly recognized as contributing to cancer progression and vascular mimicry.
B4GALT1 encodes a type II membrane-bound glycosyltransferase localized to the Golgi apparatus, where it catalyzes the transfer of galactose from UDP-galactose to terminal N-acetylglucosamine residues on glycans, generating Gal??1-4GlcNAc linkages. This reaction is fundamental to the biosynthesis of N- and O-linked glycoproteins, glycosphingolipids, and, in the presence of the cofactor alpha-lactalbumin, lactose in the mammary gland. Transcription of B4GALT1 is regulated by the SP1 and NF-Y transcription factors and is responsive to prolactin signaling. The enzymatic product modifies key downstream targets such as EGFR and integrin glycosylation, laminin processing, and glycocalyx architecture, thereby influencing cell adhesion, migration, and signal transduction. B4GALT1 function depends on interactions with manganese ions, UDP-galactose, and other Golgi-resident glycosyltransferases, integrating it into broader protein glycosylation networks.
Disruption of B4GALT1 in SK-HEP-1 cells offers a physiologically relevant system to dissect the role of galactose-containing glycans in hepatic adenocarcinoma. Given the cell line??s ability to undergo endothelial transdifferentiation, B4GALT1 knockout enables the study of how altered glycosylation governs the switch between epithelial and endothelial phenotypes, a process linked to metastatic dissemination and chemoresistance. The loss of B4GALT1 activity is expected to remodel the cell-surface glycocalyx, potentially affecting integrin-mediated adhesion, EGFR signaling, and interactions with the extracellular matrix. This model thus bridges fundamental glycobiology and cancer metastasis research, providing a platform to identify glycosylation-dependent vulnerabilities in liver cancer.
Typical applications for these polyclonal knockout cells include comparative glycosylation profiling using lectin blotting with galactose-specific lectins such as RCA I or ECA, quantitative RT-qPCR and western blotting to confirm B4GALT1 disruption, and flow cytometry with plant lectins to assess cell-surface glycan changes. The cells can be employed in N-glycan mass spectrometry workflows to map global glycosylation shifts, as well as in functional assays like cell adhesion, migration, and invasion studies to link B4GALT1-dependent glycans to metastatic behavior. Additional uses encompass investigation of glycocalyx remodeling, protein trafficking defects, and the interplay between glycosylation and oncogenic signaling pathways. For further details or technical support, please contact Ascent Research.
